About I-Mab (IMAB)
I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune ... Read more
- USD0.85
- USD0.89
- USD0.82
- USD2.00
- -3.60%
- --
- 243.26k
- 68M
- 0.60
- -53.60%
Stock News
8 hours ago
VEU: A New Golden Age For International Equities
SeekingAlpha
8 hours ago
SIL: All That Glitters Is Not Gold, Sometimes It's Silver
SeekingAlpha
8 hours ago
Carnival Corporation: Stronger Fundamentals, Speculative Upside
SeekingAlpha
9 hours ago
Brookfield Renewable: Check Out That 6.9% Yield
SeekingAlpha
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
